LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study

Anders G Olsson; Christina Lindahl; Ingar Holme; Rana Fayyad; Ole Faergeman; John J P Kastelein; Matti J Tikkanen; Mogens Lytken Larsen; Terje R Pedersen; Incremental  Decrease in End Points Through Aggressive Lipid Lowering Study Group

doi:10.1177/1741826710389391

LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study

Anders G Olsson
, Christina Lindahl
, Ingar Holme
, Rana Fayyad
, Ole Faergeman
, John J P Kastelein
, Matti J Tikkanen
, Mogens Lytken Larsen
, Terje R Pedersen
, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

We assessed the proportion of patients treated with either simvastatin 20 or 40 mg or atorvastatin 80 mg who achieved low-density lipoprotein cholesterol (LDL-C) goals of 2.5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups.

Original language	English
Journal	European Journal of Cardiovascular Prevention & Rehabilitation
Volume	18
Issue number	2
Pages (from-to)	262-9
Number of pages	8
ISSN	2047-4873
DOIs	https://doi.org/10.1177/1741826710389391
Publication status	Published - 2011

Keywords

Aged
Apolipoprotein A-I
Apolipoproteins B
Biological Markers
Cholesterol, LDL
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Myocardial Infarction
Proportional Hazards Models
Prospective Studies
Pyrroles
Recurrence
Risk Assessment
Risk Factors
Secondary Prevention
Simvastatin
Treatment Outcome

Documents & Links

10.1177/1741826710389391

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Olsson, A. G., Lindahl, C., Holme, I., Fayyad, R., Faergeman, O., Kastelein, J. J. P., Tikkanen, M. J., Larsen, M. L., Pedersen, T. R., & Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2011). LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. European Journal of Cardiovascular Prevention & Rehabilitation, 18(2), 262-9. https://doi.org/10.1177/1741826710389391

@article{94b94d9ae7bb4385b5d8e9fd84eb8b5b,

title = "LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study",

abstract = "We assessed the proportion of patients treated with either simvastatin 20 or 40 mg or atorvastatin 80 mg who achieved low-density lipoprotein cholesterol (LDL-C) goals of 2.5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups.",

keywords = "Aged, Apolipoprotein A-I, Apolipoproteins B, Biological Markers, Cholesterol, LDL, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Prospective Studies, Pyrroles, Recurrence, Risk Assessment, Risk Factors, Secondary Prevention, Simvastatin, Treatment Outcome",

author = "Olsson, \{Anders G\} and Christina Lindahl and Ingar Holme and Rana Fayyad and Ole Faergeman and Kastelein, \{John J P\} and Tikkanen, \{Matti J\} and Larsen, \{Mogens Lytken\} and Pedersen, \{Terje R\} and \{Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group\}",

year = "2011",

doi = "10.1177/1741826710389391",

language = "English",

volume = "18",

pages = "262--9",

journal = "European Journal of Cardiovascular Prevention \& Rehabilitation",

issn = "2047-4873",

publisher = "Oxford University Press",

number = "2",

}

Olsson, AG, Lindahl, C, Holme, I, Fayyad, R, Faergeman, O, Kastelein, JJP, Tikkanen, MJ, Larsen, ML, Pedersen, TR & Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group 2011, 'LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 18, no. 2, pp. 262-9. https://doi.org/10.1177/1741826710389391

TY - JOUR

T1 - LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study

AU - Olsson, Anders G

AU - Lindahl, Christina

AU - Holme, Ingar

AU - Fayyad, Rana

AU - Faergeman, Ole

AU - Kastelein, John J P

AU - Tikkanen, Matti J

AU - Larsen, Mogens Lytken

AU - Pedersen, Terje R

AU - Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group

PY - 2011

Y1 - 2011

N2 - We assessed the proportion of patients treated with either simvastatin 20 or 40 mg or atorvastatin 80 mg who achieved low-density lipoprotein cholesterol (LDL-C) goals of 2.5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups.

AB - We assessed the proportion of patients treated with either simvastatin 20 or 40 mg or atorvastatin 80 mg who achieved low-density lipoprotein cholesterol (LDL-C) goals of 2.5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups.

KW - Aged

KW - Apolipoprotein A-I

KW - Apolipoproteins B

KW - Biological Markers

KW - Cholesterol, LDL

KW - Female

KW - Heptanoic Acids

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Proportional Hazards Models

KW - Prospective Studies

KW - Pyrroles

KW - Recurrence

KW - Risk Assessment

KW - Risk Factors

KW - Secondary Prevention

KW - Simvastatin

KW - Treatment Outcome

U2 - 10.1177/1741826710389391

DO - 10.1177/1741826710389391

M3 - Journal article

C2 - 21450674

SN - 2047-4873

VL - 18

SP - 262

EP - 269

JO - European Journal of Cardiovascular Prevention & Rehabilitation

JF - European Journal of Cardiovascular Prevention & Rehabilitation

IS - 2

ER -

LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study

Abstract

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this